Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:03:55.017Z.
Calculation as of: 2026-10-06T17:03:55.017Z.
Quote observation: 2026-10-06T17:00:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 772026cfaa68636964238f2a0be34d7b7ee81ab44c33f4f711fca00153048be4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.44B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
EV/EBITDA Ratio
N/A
TTM Avg
5.67x
3Y Avg
5.67x
5Y Avg
5.67x
Market Cap
$1.46B
EV/EBITDA Ratio
8.99x
TTM Avg
18.38x
3Y Avg
16.03x
5Y Avg
16.85x
Market Cap
$1.42B
EV/EBITDA Ratio
11.43x
TTM Avg
34.83x
3Y Avg
34.83x
5Y Avg
32.76x
Market Cap
$1.42B
EV/EBITDA Ratio
25.71x
TTM Avg
25.42x
3Y Avg
27.51x
5Y Avg
46.70x
Market Cap
$1.47B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.44B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | N/A | 5.67x | 5.67x | 5.67x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.99x | 18.38x | 16.03x | 16.85x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 11.43x | 34.83x | 34.83x | 32.76x |
| Certara, Inc. (CERT)vs › | $1.46B | 26.52x | 16.63x | 66.61x | 73.09x |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 25.71x | 25.42x | 27.51x | 46.70x |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
